
Thermo Fisher Scientific (TMO) Stock
Thermo Fisher Scientific Chart
Company Profile
Price: $572.93
Market Cap: $219.15B
Exchange: NYSE
CEO: Mr. Marc N. Casper
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Employees: 122.00K
Headquarters: Waltham, MA
Website: Thermo Fisher Scientific
Business Summary
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Thermo Fisher Scientific News
Thermo Fisher Scientific: Finally Ready For A Breakout? (Upgrade)
Thermo Fisher returned to growth in 4Q 2024 across all segments, and 2025 EPS growth is projected at 6.6% supported by margin expansion. Despite rich industry valuations, Thermo trades at a discount to peers like Danaher, supported by its unique scale and breadth of offerings. Thermo looks fairly valued based on a conservative DCF analysis, but its industry leadership position and relative valuation to peers warrant an upgrade to Buy.

Thermo Fisher (TMO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Thermo Fisher (TMO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Thermo Fisher Scientific Inc. (TMO) Q4 2024 Earnings Call Transcript
Thermo Fisher Scientific Inc. (NYSE:TMO ) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Rafael Tejada - Vice President, Investor Relations Marc Casper - Chairman, President & Chief Executive Officer Stephen Williamson - Senior Vice President & Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Rachel Vatnsdal - JPMorgan Jack Meehan - Nephron Research Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Puneet Souda - Leerink Partners Operator Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2024 Fourth Quarter Conference call. My name is Ezra, and I will be your coordinator today.

Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2024 Results
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter and Full Year 2024 Highlights Fourth quarter revenue grew 5% to $11.40 billion. Fourth quarter GAAP diluted earnings per share (EPS) grew 14% to $4.78. Fourth quarter adjusted EPS grew 8% to $6.10. Full year revenue was $42.88 billion, flat versus prior year. Full year GA.

Cash Flow Focus: Thermo Fisher, Energy Transfer, and NetEase
Investors focused on top-and-bottom-line performance—important as they are—do so at the risk of neglecting another crucial metric for companies across industries: cash flow. Put simply, without adequate cash flow, it becomes difficult for any company to sustain its operations, let alone continue to grow its business through expansion, innovation, or acquisitions.

Biologicals Is The Future In Thermo Fisher: Buy Rating
Thermo Fisher Scientific is poised for growth in 2025, driven by aging demographics, higher healthcare spending, and demand for innovative biological medicines. TMO's diverse revenue streams, including life sciences, analytical instruments, specialty diagnostics, and biopharma services, ensure stability and resilience against market cycles. Thermo Fisher is a good bet for a well diversified portfolio.

Lyndra Therapeutics Announces Strategic Clinical Research and Commercial Manufacturing Services Collaboration with Thermo Fisher Scientific for Long-Acting Oral Therapies
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics, a clinical-stage biopharmaceutical company pioneering long-acting oral therapies, today announced a strategic collaboration with Thermo Fisher Scientific Inc., the world leader in serving science, in which Thermo Fisher will provide global clinical research and commercial manufacturing services to Lyndra for its long-acting oral therapies. Lyndra's long-acting oral therapies, including lead investigational product oral weekly risperidone (.

Thermo Fisher Scientific Inc. (TMO) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Thermo Fisher Scientific Inc. (NYSE:TMO ) 43rd Annual J.P. Morgan Healthcare Conference Call January 14, 2025 11:15 AM ET Company Participants Marc Casper - Chief Executive Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Rachel Vatnsdal Perfect.

Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Study
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the UK Biobank Pharma Proteomics Project (UKB-PPP) has selected its Olink® Explore Platform to support the world's largest human proteomics study of its kind. UKB-PPP aims to analyze more than 5,400 proteins from 600,000 samples to fuel the discovery of new protein biomarkers that can be used to predict, diagnose and treat diseases. “Studies on the human proteome are.

Thermo Fisher Scientific to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. (EST). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world lead.

Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 30, 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2024 before the market opens on Thursday, January 30, 2025, and will hold a conference call on the same day at 8:30 a.m. EST. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outs.

Knipper Health Announces Transfer of Commercial Sample Management Business from Thermo Fisher Scientific
LAKEWOOD, N.J.--(BUSINESS WIRE)--Knipper Health, Inc., the largest supplier of end-to-end pharmaceutical healthcare marketing services and solutions in the U.S. serving the biopharmaceutical and medical industries, announced today the Company has been assigned the assets of Patheon Pharma Services sample and fulfillment services, from Thermo Fisher Scientific, located in Memphis TN. Included in the assignment, Knipper will retain all colleagues, as well as the Memphis site, along with all custo.

Thermo Fisher: The Cycle Has Already Turned Around
Thermo Fisher's stock is now a "buy" due to signs of recovery, including positive sales growth and stabilized margins, despite recent bearish trends. The company's post-pandemic challenges are easing, with optimistic executive comments and improved guidance for 2024, indicating a potential return to organic growth. Potential deregulation under Trump's administration could benefit Thermo Fisher by increasing demand for its equipment and consumables in a more competitive pharmaceutical market.

Thermo Fisher Scientific: Renewed Growth Momentum After The Pandemic
Thermo Fisher Scientific is well-positioned for growth due to its consistent revenue streams, strong M&A track record and minimal macroeconomic dependence. Despite a COVID-related revenue surge and subsequent correction, the company's valuation multiples are now reasonable, offering potential for capital appreciation. 2025 growth drivers include improved biotech funding and China's government stimulus.

Thermo Fisher Scientific Earnings
This section highlights Thermo Fisher Scientific's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
---|---|---|---|---|---|
Read Transcript | Q4 | 2024 | 2025-01-30 | $5.94 | $6.10 |
Read Transcript | Q3 | 2024 | 2024-10-23 | $5.25 | $5.28 |
Read Transcript | Q2 | 2024 | 2024-07-24 | $5.12 | $5.37 |
Read Transcript | Q1 | 2024 | 2024-04-24 | $4.71 | $5.11 |
Read Transcript | Q4 | 2023 | 2024-01-31 | $5.64 | $5.67 |
Read Transcript | Q3 | 2023 | 2023-10-25 | $5.61 | $5.69 |
Read Transcript | Q2 | 2023 | 2023-07-26 | $5.43 | $5.15 |
Read Transcript | Q1 | 2023 | 2023-04-26 | $4.95 | $5.03 |
Financial Statements
Access annual & quarterly financial statements for Thermo Fisher Scientific, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
---|---|---|---|---|---|
Revenue | $42.88B | $42.86B | $44.91B | $39.21B | $32.22B |
Cost of Revenue | $24.82B | $25.74B | $25.41B | $18.98B | $15.71B |
Gross Profit | $18.06B | $17.11B | $19.50B | $20.23B | $16.50B |
Gross Profit Ratio | 42.12% | 39.93% | 43.42% | 51.60% | 51.23% |
Research and Development Expenses | $1.39B | $1.34B | $1.47B | $1.41B | $1.18B |
General and Administrative Expenses | $- | $- | $- | $- | $- |
Selling and Marketing Expenses | $- | $- | $- | $- | $- |
Selling General and Administrative Expenses | $7.00B | $8.45B | $7.13B | $6.84B | $5.76B |
Other Expenses | $2.33B | $472.00M | $2.40B | $1.76B | $1.67B |
Operating Expenses | $10.72B | $10.25B | $10.99B | $10.01B | $8.61B |
Cost and Expenses | $35.54B | $36.00B | $36.41B | $28.99B | $24.32B |
Interest Income | $1.08B | $879.00M | $272.00M | $43.00M | $65.00M |
Interest Expense | $-1.39B | $1.38B | $726.00M | $536.00M | $553.00M |
Depreciation and Amortization | $- | $3.41B | $3.38B | $2.59B | $2.33B |
EBITDA | $7.34B | $11.08B | $11.94B | $12.96B | $10.19B |
EBITDA Ratio | 17.11% | 25.85% | 26.84% | 31.03% | 31.67% |
Operating Income | $7.34B | $6.86B | $8.39B | $10.03B | $7.79B |
Operating Income Ratio | 17.11% | 16.00% | 18.69% | 25.57% | 24.19% |
Total Other Income Expenses Net | $-300.00M | $-561.00M | $-558.00M | $-1.19B | $-567.00M |
Income Before Tax | $7.04B | $6.30B | $7.83B | $8.84B | $7.22B |
Income Before Tax Ratio | 16.41% | 14.70% | 17.44% | 22.55% | 22.43% |
Income Tax Expense | $-657.00M | $284.00M | $703.00M | $1.11B | $850.00M |
Net Income | $6.33B | $6.00B | $6.95B | $7.72B | $6.38B |
Net Income Ratio | 14.77% | 13.99% | 15.47% | 19.70% | 19.79% |
EPS | $16.58 | $15.53 | $17.73 | $19.61 | $16.10 |
EPS Diluted | $16.54 | $15.45 | $17.64 | $19.46 | $15.98 |
Weighted Average Shares Outstanding | 382.00M | 386.00M | 392.00M | 394.00M | 396.00M |
Weighted Average Shares Outstanding Diluted | 383.00M | 388.00M | 394.00M | 397.00M | 399.00M |
SEC Filing | Source | Source | Source | Source | Source |
Income Statement Charts
Breakdown | December 31, 2024 | September 28, 2024 | June 29, 2024 | March 30, 2024 | December 31, 2023 | September 30, 2023 | July 01, 2023 | April 01, 2023 | December 31, 2022 | October 01, 2022 | July 02, 2022 | April 02, 2022 | December 31, 2021 | October 02, 2021 | July 03, 2021 | April 03, 2021 | December 31, 2020 | September 26, 2020 | June 27, 2020 | March 28, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $11.39B | $10.60B | $10.54B | $10.35B | $10.89B | $10.57B | $10.69B | $10.71B | $11.45B | $10.68B | $10.97B | $11.82B | $10.70B | $9.33B | $9.27B | $9.91B | $10.55B | $8.52B | $6.92B | $6.23B |
Cost of Revenue | $6.49B | $6.27B | $6.20B | $6.13B | $6.39B | $6.14B | $6.32B | $6.44B | $6.71B | $6.25B | $6.24B | $6.21B | $5.30B | $4.53B | $4.58B | $4.56B | $4.87B | $4.07B | $3.42B | $3.37B |
Gross Profit | $4.90B | $4.33B | $4.34B | $4.22B | $4.50B | $4.43B | $4.36B | $4.27B | $4.74B | $4.43B | $4.73B | $5.60B | $5.40B | $4.80B | $4.69B | $5.35B | $5.68B | $4.46B | $3.50B | $2.87B |
Gross Profit Ratio | 43.03% | 40.84% | 41.21% | 40.76% | 41.30% | 41.89% | 40.83% | 39.90% | 41.35% | 41.50% | 43.12% | 47.42% | 50.46% | 51.41% | 50.56% | 54.00% | 53.87% | 52.29% | 50.61% | 45.99% |
Research and Development Expenses | $374.00M | $346.00M | $339.00M | $331.00M | $327.00M | $319.00M | $345.00M | $346.00M | $391.00M | $351.00M | $365.00M | $364.00M | $392.00M | $351.00M | $343.00M | $320.00M | $376.00M | $296.00M | $264.00M | $245.00M |
General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Selling General and Administrative Expenses | $1.85B | $2.10B | $2.25B | $2.17B | $1.67B | $1.58B | $1.67B | $1.65B | $1.84B | $1.74B | $1.74B | $1.81B | $1.96B | $1.73B | $1.61B | $1.54B | $1.79B | $1.30B | $1.42B | $1.25B |
Other Expenses | $667.00M | $46.00M | $5.00M | $10.00M | $643.00M | $14.00M | $768.00M | $606.00M | $592.00M | $594.00M | $600.00M | $609.00M | $-526.00M | $14.00M | $-5.00M | $-183.00M | $-45.00M | $-39.00M | $-9.00M | $12.00M |
Operating Expenses | $2.89B | $2.49B | $2.59B | $2.50B | $2.64B | $2.48B | $2.60B | $2.60B | $2.82B | $2.69B | $2.71B | $2.78B | $2.82B | $2.50B | $2.41B | $2.29B | $2.58B | $2.01B | $2.10B | $1.92B |
Cost and Expenses | $9.38B | $8.76B | $8.78B | $8.62B | $9.03B | $8.63B | $8.93B | $9.04B | $9.53B | $8.93B | $8.95B | $8.99B | $8.12B | $7.03B | $6.99B | $6.84B | $7.45B | $6.08B | $5.51B | $5.29B |
Interest Income | $227.00M | $277.00M | $295.00M | $279.00M | $309.00M | $246.00M | $178.00M | $146.00M | $150.00M | $68.00M | $36.00M | $18.00M | $11.00M | $9.00M | $11.00M | $12.00M | $12.00M | $9.00M | $8.00M | $36.00M |
Interest Expense | $-316.00M | $356.00M | $354.00M | $363.00M | $390.00M | $359.00M | $326.00M | $300.00M | $269.00M | $173.00M | $148.00M | $136.00M | $161.00M | $128.00M | $122.00M | $125.00M | $146.00M | $144.00M | $137.00M | $126.00M |
Depreciation and Amortization | $- | $740.00M | $790.00M | $836.00M | $839.00M | $853.00M | $855.00M | $859.00M | $848.00M | $838.00M | $836.00M | $859.00M | $683.00M | $628.00M | $660.00M | $621.00M | $602.00M | $575.00M | $574.00M | $574.00M |
EBITDA | $2.02B | $2.91B | $2.98B | $2.56B | $2.87B | $2.80B | $2.64B | $2.58B | $2.88B | $2.56B | $2.82B | $3.69B | $3.44B | $2.95B | $2.88B | $3.71B | $3.69B | $3.01B | $1.98B | $1.52B |
EBITDA Ratio | 17.69% | 27.42% | 24.17% | 24.71% | 17.03% | 28.95% | 26.14% | 24.59% | 25.76% | 24.77% | 26.66% | 29.93% | 25.71% | 31.59% | 31.79% | 35.46% | 34.81% | 35.07% | 28.57% | 25.14% |
Operating Income | $2.02B | $1.84B | $1.76B | $1.72B | $1.85B | $1.86B | $1.58B | $1.56B | $1.86B | $1.71B | $2.00B | $2.82B | $2.54B | $2.28B | $2.16B | $3.05B | $3.07B | $2.43B | $1.39B | $906.00M |
Operating Income Ratio | 17.69% | 17.34% | 16.68% | 16.63% | 17.03% | 17.63% | 14.77% | 14.59% | 16.25% | 16.02% | 18.24% | 23.87% | 23.72% | 24.42% | 23.33% | 30.78% | 29.11% | 28.47% | 20.11% | 14.54% |
Total Other Income Expenses Net | $-75.00M | $-96.00M | $-55.00M | $-74.00M | $-114.00M | $-99.00M | $-148.00M | $-200.00M | $-84.00M | $-109.00M | $-84.00M | $-281.00M | $-676.00M | $-105.00M | $-116.00M | $-296.00M | $-179.00M | $-174.00M | $-138.00M | $-78.00M |
Income Before Tax | $1.94B | $1.74B | $1.76B | $1.59B | $1.74B | $1.76B | $1.43B | $1.36B | $1.78B | $1.60B | $1.92B | $2.54B | $1.86B | $2.17B | $2.05B | $2.75B | $2.89B | $2.25B | $1.25B | $828.00M |
Income Before Tax Ratio | 17.03% | 16.44% | 16.74% | 15.36% | 15.98% | 16.69% | 13.38% | 12.73% | 15.52% | 14.99% | 17.47% | 21.49% | 17.40% | 23.29% | 22.07% | 27.79% | 27.41% | 26.43% | 18.11% | 13.29% |
Income Tax Expense | $-150.00M | $99.00M | $128.00M | $281.00M | $-133.00M | $53.00M | $52.00M | $46.00M | $173.00M | $31.00M | $198.00M | $301.00M | $202.00M | $271.00M | $219.00M | $416.00M | $394.00M | $319.00M | $97.00M | $40.00M |
Net Income | $1.83B | $1.63B | $1.55B | $1.33B | $1.63B | $1.72B | $1.36B | $1.29B | $1.58B | $1.50B | $1.66B | $2.21B | $1.66B | $1.90B | $1.83B | $2.34B | $2.50B | $1.93B | $1.16B | $788.00M |
Net Income Ratio | 16.06% | 15.38% | 14.69% | 12.84% | 14.97% | 16.22% | 12.74% | 12.04% | 13.76% | 14.00% | 15.17% | 18.74% | 15.49% | 20.39% | 19.71% | 23.59% | 23.68% | 22.69% | 16.71% | 12.65% |
EPS | $4.79 | $4.27 | $4.05 | $3.48 | $4.21 | $4.44 | $3.53 | $3.34 | $4.03 | $3.81 | $4.24 | $5.65 | $4.20 | $4.83 | $4.65 | $5.93 | $6.30 | $4.88 | $2.92 | $1.99 |
EPS Diluted | $4.78 | $4.24 | $4.04 | $3.46 | $4.20 | $4.42 | $3.51 | $3.32 | $4.01 | $3.78 | $4.22 | $5.61 | $4.17 | $4.79 | $4.61 | $5.88 | $6.24 | $4.84 | $2.90 | $1.97 |
Weighted Average Shares Outstanding | 382.00M | 382.00M | 382.00M | 382.00M | 387.00M | 386.00M | 386.00M | 386.00M | 391.00M | 392.00M | 392.00M | 392.00M | 394.00M | 394.00M | 393.00M | 394.00M | 397.00M | 396.00M | 395.00M | 397.00M |
Weighted Average Shares Outstanding Diluted | 383.00M | 384.00M | 383.00M | 384.00M | 388.00M | 388.00M | 388.00M | 388.00M | 393.00M | 395.00M | 394.00M | 395.00M | 398.00M | 397.00M | 396.00M | 397.00M | 400.00M | 399.00M | 398.00M | 400.00M |
SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Cash and Cash Equivalents | $8.08B | $8.52B | $4.48B | $10.32B | $2.40B |
Short Term Investments | $-1.97B | $- | $- | $- | $- |
Cash and Short Term Investments | $8.08B | $8.52B | $4.48B | $10.32B | $2.40B |
Net Receivables | $9.66B | $9.43B | $8.95B | $6.47B | $4.95B |
Inventory | $5.09B | $5.63B | $5.05B | $4.03B | $3.37B |
Other Current Assets | $1.76B | $1.64B | $1.64B | $1.13B | $1.17B |
Total Current Assets | $24.59B | $25.23B | $20.11B | $21.96B | $11.89B |
Property Plant Equipment Net | $9.45B | $10.87B | $9.86B | $6.69B | $5.45B |
Goodwill | $44.02B | $41.20B | $41.92B | $26.04B | $25.71B |
Intangible Assets | $16.67B | $17.48B | $20.15B | $12.69B | $14.01B |
Goodwill and Intangible Assets | $60.69B | $58.67B | $62.07B | $38.73B | $39.73B |
Long Term Investments | $45.00M | $154.00M | $63.00M | $53.00M | $67.00M |
Tax Assets | $- | $2.85B | $-4.35B | $-2.46B | $-1.85B |
Other Non-Current Assets | $3.95B | $-2.85B | $4.35B | $2.46B | $1.85B |
Total Non-Current Assets | $74.14B | $69.70B | $72.00B | $45.47B | $45.24B |
Other Assets | $- | $2.22B | $3.01B | $1.63B | $1.25B |
Total Assets | $98.73B | $97.15B | $95.12B | $69.05B | $58.38B |
Account Payables | $2.87B | $3.38B | $2.87B | $2.17B | $1.92B |
Short Term Debt | $3.60B | $5.58B | $2.54B | $2.81B | $676.00M |
Tax Payables | $- | $- | $- | $- | $- |
Deferred Revenue | $2.69B | $2.60B | $2.65B | $1.27B | $916.00M |
Other Current Liabilities | $4.85B | $5.45B | $5.38B | $3.86B | $2.69B |
Total Current Liabilities | $14.01B | $17.01B | $13.44B | $10.30B | $6.20B |
Long Term Debt | $31.31B | $28.91B | $32.15B | $19.73B | $17.65B |
Deferred Revenue Non-Current | $- | $-7.12B | $-52.83B | $-6.93B | $-7.43B |
Deferred Tax Liabilities Non-Current | $1.92B | $2.85B | $3.84B | $1.79B | $2.19B |
Other Non-Current Liabilities | $4.64B | $4.24B | $4.72B | $2.70B | $2.67B |
Total Non-Current Liabilities | $37.87B | $28.80B | $32.15B | $19.15B | $17.09B |
Other Liabilities | $- | $7.20B | $8.56B | $5.08B | $5.42B |
Total Liabilities | $51.88B | $53.01B | $54.15B | $34.53B | $28.71B |
Preferred Stock | $- | $3.10B | $2.33B | $2.81B | $2.68B |
Common Stock | $442.00M | $441.00M | $439.00M | $437.00M | $434.00M |
Retained Earnings | $47.36B | $41.91B | $35.43B | $28.12B | $22.09B |
Accumulated Other Comprehensive Income Loss | $-3.22B | $-3.10B | $-2.33B | $-2.81B | $-2.68B |
Other Total Stockholders Equity | $2.15B | $4.73B | $7.25B | $8.76B | $9.83B |
Total Stockholders Equity | $46.73B | $43.98B | $40.79B | $34.51B | $29.68B |
Total Equity | $46.84B | $44.15B | $40.98B | $34.52B | $29.68B |
Total Liabilities and Stockholders Equity | $98.73B | $97.15B | $95.12B | $69.05B | $58.38B |
Minority Interest | $107.00M | $170.00M | $184.00M | $10.00M | $- |
Total Liabilities and Total Equity | $98.73B | $97.15B | $95.12B | $69.05B | $58.38B |
Total Investments | $-1.92B | $154.00M | $63.00M | $53.00M | $67.00M |
Total Debt | $34.92B | $34.49B | $34.87B | $21.73B | $17.75B |
Net Debt | $26.84B | $25.96B | $30.39B | $11.41B | $15.35B |
Balance Sheet Charts
Breakdown | December 31, 2024 | September 28, 2024 | June 29, 2024 | March 30, 2024 | December 31, 2023 | September 30, 2023 | July 01, 2023 | April 01, 2023 | December 31, 2022 | October 01, 2022 | July 02, 2022 | April 02, 2022 | December 31, 2021 | October 02, 2021 | July 03, 2021 | April 03, 2021 | December 31, 2020 | September 26, 2020 | June 27, 2020 | March 28, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash and Cash Equivalents | $4.01B | $4.64B | $7.08B | $5.51B | $8.08B | $6.15B | $3.13B | $3.48B | $8.52B | $2.92B | $1.89B | $2.75B | $4.48B | $12.03B | $7.02B | $5.58B | $10.32B | $7.54B | $5.82B | $2.98B |
Short Term Investments | $1.56B | $2.00B | $1.75B | $1.75B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Cash and Short Term Investments | $5.57B | $6.64B | $8.83B | $7.26B | $8.08B | $6.15B | $3.13B | $3.48B | $8.52B | $2.92B | $1.89B | $2.75B | $4.48B | $12.03B | $7.02B | $5.58B | $10.32B | $7.54B | $5.82B | $2.98B |
Net Receivables | $8.19B | $9.80B | $9.43B | $9.35B | $9.66B | $9.84B | $9.49B | $9.30B | $9.43B | $8.92B | $8.89B | $8.95B | $8.95B | $6.37B | $6.28B | $6.34B | $6.47B | $5.88B | $5.16B | $5.17B |
Inventory | $4.98B | $5.43B | $5.20B | $5.13B | $5.09B | $5.40B | $5.66B | $5.66B | $5.63B | $5.72B | $5.67B | $5.48B | $5.05B | $4.91B | $4.62B | $4.34B | $4.03B | $3.83B | $3.65B | $3.45B |
Other Current Assets | $3.40B | $1.91B | $2.02B | $1.90B | $1.76B | $1.70B | $1.72B | $1.77B | $1.64B | $1.74B | $1.65B | $1.59B | $1.64B | $1.43B | $1.33B | $1.42B | $1.13B | $982.00M | $1.15B | $1.14B |
Total Current Assets | $22.14B | $23.78B | $25.48B | $23.64B | $24.59B | $23.09B | $20.00B | $20.21B | $25.23B | $19.30B | $18.10B | $18.78B | $20.11B | $24.72B | $19.26B | $17.68B | $21.96B | $18.23B | $15.78B | $12.74B |
Property Plant Equipment Net | $9.31B | $9.41B | $9.28B | $9.32B | $9.45B | $9.17B | $9.29B | $9.35B | $10.87B | $8.63B | $8.53B | $8.45B | $9.86B | $7.05B | $6.56B | $6.13B | $6.69B | $5.18B | $4.89B | $4.74B |
Goodwill | $45.85B | $46.73B | $43.84B | $43.84B | $44.02B | $43.58B | $43.27B | $43.14B | $41.20B | $40.49B | $41.07B | $41.72B | $41.92B | $26.91B | $26.90B | $26.82B | $26.04B | $25.78B | $25.70B | $25.61B |
Intangible Assets | $15.53B | $16.26B | $15.52B | $16.05B | $16.67B | $17.09B | $17.44B | $17.97B | $17.48B | $17.81B | $18.58B | $19.38B | $20.15B | $11.93B | $12.39B | $12.83B | $12.69B | $12.87B | $13.17B | $13.54B |
Goodwill and Intangible Assets | $61.39B | $62.99B | $59.36B | $59.89B | $60.69B | $60.67B | $60.71B | $61.11B | $58.67B | $58.30B | $59.64B | $61.10B | $62.07B | $38.84B | $39.29B | $39.65B | $38.73B | $38.65B | $38.87B | $39.16B |
Long Term Investments | $- | $- | $492.00M | $233.00M | $59.00M | $87.00M | $6.00M | $50.00M | $154.00M | $145.00M | $98.00M | $49.00M | $63.00M | $10.00M | $74.00M | $2.00M | $53.00M | $39.00M | $64.00M | $65.00M |
Tax Assets | $- | $1.12B | $1.52B | $1.81B | $-59.00M | $2.62B | $2.84B | $2.98B | $2.85B | $-1.17B | $-979.00M | $-4.42B | $3.84B | $1.47B | $1.63B | $1.89B | $-2.46B | $1.53B | $1.75B | $2.14B |
Other Non-Current Assets | $4.49B | $3.06B | $2.37B | $2.20B | $4.00B | $-2.62B | $-2.84B | $-2.98B | $-2.85B | $1.17B | $979.00M | $4.42B | $-3.84B | $-1.47B | $-1.71B | $-1.89B | $2.46B | $-1.53B | $-1.75B | $-2.14B |
Total Non-Current Assets | $75.18B | $76.58B | $73.02B | $73.45B | $74.14B | $69.93B | $70.01B | $70.52B | $69.70B | $67.07B | $68.27B | $69.60B | $72.00B | $45.90B | $45.85B | $45.79B | $45.47B | $43.87B | $43.82B | $43.96B |
Other Assets | $- | $- | $- | $- | $- | $4.04B | $4.10B | $3.93B | $2.22B | $4.16B | $4.21B | $4.38B | $3.01B | $2.98B | $2.58B | $2.46B | $1.63B | $1.96B | $2.00B | $1.99B |
Total Assets | $97.32B | $100.36B | $98.50B | $97.09B | $98.73B | $97.06B | $94.11B | $94.66B | $97.15B | $90.54B | $90.58B | $92.75B | $95.12B | $73.60B | $67.70B | $65.93B | $69.05B | $64.06B | $61.59B | $58.69B |
Account Payables | $- | $2.61B | $2.55B | $2.56B | $2.87B | $2.51B | $2.42B | $2.80B | $3.38B | $2.47B | $2.59B | $2.67B | $2.87B | $2.30B | $2.10B | $2.15B | $2.17B | $1.70B | $1.39B | $1.60B |
Short Term Debt | $2.21B | $4.12B | $5.12B | $4.45B | $3.61B | $4.79B | $4.81B | $6.12B | $5.58B | $1.01B | $1.01B | $1.88B | $2.52B | $19.00M | $4.00M | $4.00M | $2.81B | $2.00M | $675.00M | $738.00M |
Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Deferred Revenue | $- | $2.66B | $2.59B | $2.63B | $2.69B | $2.55B | $2.59B | $2.66B | $2.60B | $2.57B | $2.72B | $2.87B | $2.65B | $1.44B | $1.47B | $1.40B | $1.27B | $1.05B | $975.00M | $938.00M |
Other Current Liabilities | $11.12B | $5.22B | $4.51B | $4.30B | $4.84B | $4.31B | $4.29B | $4.30B | $5.45B | $5.07B | $4.68B | $4.64B | $5.39B | $3.99B | $3.35B | $3.45B | $3.86B | $3.48B | $2.98B | $2.23B |
Total Current Liabilities | $13.33B | $14.60B | $14.77B | $13.94B | $14.01B | $14.16B | $14.11B | $15.88B | $17.01B | $11.12B | $11.00B | $12.07B | $13.44B | $7.75B | $6.92B | $7.00B | $10.30B | $6.23B | $6.01B | $5.50B |
Long Term Debt | $29.06B | $31.20B | $30.49B | $31.16B | $31.31B | $30.49B | $29.19B | $29.14B | $28.91B | $28.37B | $29.45B | $31.57B | $32.15B | $21.80B | $18.77B | $18.64B | $19.74B | $21.09B | $20.64B | $19.23B |
Deferred Revenue Non-Current | $- | $1.43B | $1.46B | $1.43B | $-1.92B | $-9.57B | $-9.73B | $-7.21B | $-7.12B | $-7.54B | $-7.86B | $-49.17B | $1.24B | $822.00M | $781.00M | $-7.12B | $-6.93B | $-6.45B | $-6.82B | $-7.54B |
Deferred Tax Liabilities Non-Current | $- | $1.12B | $1.52B | $1.81B | $1.92B | $2.62B | $2.84B | $2.98B | $2.85B | $3.14B | $3.33B | $3.49B | $3.84B | $1.47B | $1.63B | $1.89B | $1.79B | $1.53B | $1.75B | $2.14B |
Other Non-Current Liabilities | $5.38B | $2.92B | $4.18B | $4.57B | $4.64B | $2.98B | $4.04B | $4.23B | $4.24B | $4.18B | $4.33B | $4.48B | $4.72B | $3.88B | $3.51B | $3.35B | $2.70B | $3.39B | $3.32B | $3.26B |
Total Non-Current Liabilities | $34.44B | $36.66B | $36.19B | $37.53B | $37.87B | $30.44B | $29.01B | $29.01B | $28.80B | $27.93B | $29.05B | $31.21B | $32.15B | $21.58B | $18.79B | $18.65B | $19.15B | $21.11B | $20.67B | $19.26B |
Other Liabilities | $- | $- | $- | $- | $- | $6.99B | $7.07B | $7.33B | $7.20B | $7.76B | $8.06B | $8.34B | $8.56B | $5.55B | $5.13B | $5.23B | $5.08B | $4.90B | $5.03B | $5.37B |
Total Liabilities | $47.77B | $51.27B | $50.96B | $51.47B | $51.88B | $51.59B | $50.19B | $52.23B | $53.01B | $46.81B | $48.11B | $51.62B | $54.15B | $34.89B | $30.84B | $30.87B | $34.53B | $32.24B | $31.72B | $30.13B |
Preferred Stock | $- | $- | $- | $- | $- | $3.03B | $2.92B | $3.05B | $3.10B | $2.93B | $2.72B | $2.34B | $2.33B | $2.65B | $2.63B | $2.56B | $2.81B | $2.97B | $2.99B | $3.09B |
Common Stock | $- | $444.00M | $443.00M | $443.00M | $442.00M | $442.00M | $441.00M | $441.00M | $441.00M | $440.00M | $440.00M | $440.00M | $439.00M | $439.00M | $438.00M | $438.00M | $437.00M | $437.00M | $436.00M | $435.00M |
Retained Earnings | $- | $51.42B | $49.94B | $48.54B | $47.36B | $45.87B | $44.29B | $43.06B | $41.91B | $40.45B | $39.07B | $37.53B | $35.43B | $33.88B | $32.08B | $30.35B | $28.12B | $25.70B | $23.86B | $22.79B |
Accumulated Other Comprehensive Income Loss | $- | $-2.48B | $-2.41B | $-2.76B | $-3.22B | $-3.03B | $-2.92B | $-3.05B | $-3.10B | $-2.93B | $-2.72B | $-2.34B | $-2.33B | $-2.65B | $-2.63B | $-2.56B | $-2.81B | $-2.97B | $-2.99B | $-3.09B |
Other Total Stockholders Equity | $49.55B | $-396.00M | $-538.00M | $-705.00M | $2.15B | $2.04B | $1.95B | $1.81B | $4.73B | $5.58B | $5.50B | $5.33B | $7.25B | $7.05B | $6.97B | $6.83B | $8.76B | $8.65B | $8.57B | $8.42B |
Total Stockholders Equity | $49.55B | $48.99B | $47.43B | $45.52B | $46.72B | $45.33B | $43.75B | $42.26B | $43.98B | $43.55B | $42.29B | $40.96B | $40.79B | $38.71B | $36.85B | $35.06B | $34.51B | $31.82B | $29.88B | $28.56B |
Total Equity | $49.67B | $49.10B | $47.53B | $45.62B | $46.84B | $45.46B | $43.91B | $42.43B | $44.15B | $43.73B | $42.47B | $41.13B | $40.98B | $38.71B | $36.85B | $35.06B | $34.52B | $31.82B | $29.88B | $28.56B |
Total Liabilities and Stockholders Equity | $97.32B | $100.36B | $98.50B | $97.09B | $98.73B | $97.06B | $94.11B | $94.66B | $97.15B | $90.54B | $90.58B | $92.75B | $95.12B | $73.60B | $67.70B | $65.93B | $69.05B | $64.06B | $61.59B | $58.69B |
Minority Interest | $120.00M | $107.00M | $103.00M | $107.00M | $118.00M | $136.00M | $163.00M | $176.00M | $170.00M | $178.00M | $178.00M | $175.00M | $184.00M | $- | $- | $- | $10.00M | $- | $- | $- |
Total Liabilities and Total Equity | $97.32B | $100.36B | $98.50B | $97.09B | $98.73B | $97.06B | $94.11B | $94.66B | $97.15B | $90.54B | $90.58B | $92.75B | $95.12B | $73.60B | $67.70B | $65.93B | $69.05B | $64.06B | $61.59B | $58.69B |
Total Investments | $1.56B | $2.00B | $2.24B | $1.98B | $59.00M | $87.00M | $6.00M | $50.00M | $154.00M | $145.00M | $98.00M | $49.00M | $63.00M | $10.00M | $74.00M | $2.00M | $53.00M | $39.00M | $64.00M | $65.00M |
Total Debt | $31.27B | $35.31B | $35.41B | $35.61B | $34.92B | $35.28B | $34.01B | $35.26B | $34.49B | $29.16B | $30.26B | $33.26B | $34.87B | $21.71B | $18.78B | $18.64B | $21.73B | $21.09B | $21.31B | $19.97B |
Net Debt | $27.27B | $30.67B | $28.32B | $30.10B | $26.84B | $29.13B | $30.88B | $31.77B | $25.96B | $26.24B | $28.37B | $30.50B | $30.39B | $9.68B | $11.75B | $13.06B | $11.41B | $13.55B | $15.49B | $16.99B |
Annual Cash Flow
Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
---|---|---|---|---|---|
Net Income | $6.34B | $6.00B | $6.96B | $7.73B | $6.38B |
Depreciation and Amortization | $3.11B | $3.41B | $3.38B | $2.59B | $2.33B |
Deferred Income Tax | $-1.21B | $-1.30B | $-995.00M | $-406.00M | $-552.00M |
Stock Based Compensation | $- | $278.00M | $307.00M | $230.00M | $196.00M |
Change in Working Capital | $- | $-537.00M | $-1.05B | $-1.56B | $-395.00M |
Accounts Receivables | $- | $209.00M | $-430.00M | $-204.00M | $-1.30B |
Inventory | $- | $598.00M | $-825.00M | $-1.06B | $-508.00M |
Accounts Payables | $- | $-500.00M | $648.00M | $479.00M | $59.00M |
Other Working Capital | $- | $-844.00M | $-442.00M | $-768.00M | $1.36B |
Other Non Cash Items | $430.00M | $564.00M | $550.00M | $957.00M | $340.00M |
Net Cash Provided by Operating Activities | $8.67B | $8.41B | $9.15B | $9.54B | $8.29B |
Investments in Property Plant and Equipment | $-1.40B | $-1.48B | $-2.24B | $-2.52B | $-1.47B |
Acquisitions Net | $-3.13B | $-3.66B | $-39.00M | $-19.39B | $-38.00M |
Purchases of Investments | $-3.40B | $- | $-15.00M | $-8.00M | $- |
Sales Maturities of Investments | $1.77B | $70.00M | $15.00M | $8.00M | $- |
Other Investing Activities | $317.00M | $-73.00M | $123.00M | $-14.00M | $2.00M |
Net Cash Used for Investing Activities | $-5.84B | $-5.14B | $-2.16B | $-21.93B | $-1.51B |
Debt Repayment | $- | $-155.00M | $654.00M | $8.91B | $2.75B |
Common Stock Issued | $- | $- | $- | $- | $- |
Common Stock Repurchased | $-4.00B | $-3.00B | $-3.00B | $-2.00B | $-1.50B |
Dividends Paid | $-583.00M | $-523.00M | $-455.00M | $-395.00M | $-337.00M |
Other Financing Activities | $-6.21B | $56.00M | $-9.00M | $65.00M | $46.00M |
Net Cash Used Provided by Financing Activities | $-6.79B | $-3.62B | $-2.81B | $6.58B | $959.00M |
Effect of Forex Changes on Cash | $-91.00M | $-82.00M | $-139.00M | $-37.00M | $176.00M |
Net Change in Cash | $-4.06B | $-440.00M | $4.05B | $-5.84B | $7.91B |
Cash at End of Period | $4.04B | $8.10B | $8.54B | $4.49B | $10.34B |
Cash at Beginning of Period | $8.10B | $8.54B | $4.49B | $10.34B | $2.42B |
Operating Cash Flow | $8.67B | $8.41B | $9.15B | $9.54B | $8.29B |
Capital Expenditure | $-1.40B | $-1.48B | $-2.24B | $-2.52B | $-1.47B |
Free Cash Flow | $7.27B | $6.93B | $6.91B | $7.02B | $6.82B |
Cash Flow Charts
Breakdown | September 28, 2024 | June 29, 2024 | March 30, 2024 | December 31, 2023 | September 30, 2023 | July 01, 2023 | April 01, 2023 | December 31, 2022 | October 01, 2022 | July 02, 2022 | April 02, 2022 | December 31, 2021 | October 02, 2021 | July 03, 2021 | April 03, 2021 | December 31, 2020 | September 26, 2020 | June 27, 2020 | March 28, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | $1.63B | $1.55B | $1.33B | $1.63B | $1.70B | $1.36B | $1.29B | $1.57B | $1.50B | $1.67B | $2.22B | $1.66B | $1.90B | $1.83B | $2.34B | $2.50B | $1.93B | $1.16B | $788.00M | $1.00B |
Depreciation and Amortization | $740.00M | $790.00M | $836.00M | $839.00M | $853.00M | $855.00M | $859.00M | $848.00M | $838.00M | $836.00M | $859.00M | $683.00M | $628.00M | $660.00M | $621.00M | $602.00M | $575.00M | $574.00M | $574.00M | $576.00M |
Deferred Income Tax | $-400.00M | $-354.00M | $-253.00M | $-669.00M | $-303.00M | $-182.00M | $-146.00M | $-133.00M | $-261.00M | $-262.00M | $-339.00M | $49.00M | $-148.00M | $-331.00M | $24.00M | $-56.00M | $-178.00M | $-277.00M | $-41.00M | $8.00M |
Stock Based Compensation | $68.00M | $84.00M | $70.00M | $61.00M | $67.00M | $74.00M | $76.00M | $75.00M | $77.00M | $77.00M | $78.00M | $77.00M | $51.00M | $51.00M | $51.00M | $51.00M | $52.00M | $47.00M | $46.00M | $43.00M |
Change in Working Capital | $1.00B | $-216.00M | $-787.00M | $1.72B | $-9.00M | $-718.00M | $-1.53B | $1.04B | $-367.00M | $-849.00M | $-875.00M | $-348.00M | $237.00M | $-126.00M | $-1.32B | $113.00M | $226.00M | $341.00M | $-1.07B | $135.00M |
Accounts Receivables | $- | $- | $- | $209.00M | $- | $- | $- | $-430.00M | $- | $- | $- | $-204.00M | $- | $- | $- | $-444.00M | $-663.00M | $23.00M | $-218.00M | $96.00M |
Inventory | $- | $- | $- | $598.00M | $- | $- | $- | $-825.00M | $- | $- | $- | $-1.06B | $- | $- | $- | $-81.00M | $-118.00M | $-168.00M | $-141.00M | $-9.00M |
Accounts Payables | $- | $- | $- | $-500.00M | $- | $- | $- | $648.00M | $- | $- | $- | $479.00M | $- | $- | $- | $279.00M | $277.00M | $-256.00M | $-241.00M | $196.00M |
Other Working Capital | $1.00B | $-216.00M | $-787.00M | $1.42B | $-9.00M | $-718.00M | $-1.53B | $1.65B | $-367.00M | $-849.00M | $-875.00M | $442.00M | $237.00M | $-126.00M | $-1.32B | $359.00M | $730.00M | $742.00M | $-475.00M | $-148.00M |
Other Non Cash Items | $-874.00M | $1.77B | $1.80B | $139.00M | $328.00M | $299.00M | $181.00M | $81.00M | $152.00M | $58.00M | $259.00M | $566.00M | $-20.00M | $145.00M | $266.00M | $131.00M | $100.00M | $45.00M | $64.00M | $149.00M |
Net Cash Provided by Operating Activities | $2.17B | $1.96B | $1.25B | $3.72B | $2.41B | $1.54B | $729.00M | $3.49B | $1.94B | $1.53B | $2.20B | $2.69B | $2.65B | $2.23B | $1.98B | $3.34B | $2.71B | $1.89B | $356.00M | $1.91B |
Investments in Property Plant and Equipment | $-272.00M | $-301.00M | $-347.00M | $-405.00M | $-332.00M | $-284.00M | $-458.00M | $-550.00M | $-547.00M | $-506.00M | $-640.00M | $-831.00M | $-524.00M | $-540.00M | $-628.00M | $-586.00M | $-366.00M | $-269.00M | $-253.00M | $-289.00M |
Acquisitions Net | $-3.11B | $16.00M | $4.00M | $11.00M | $-909.00M | $-47.00M | $-2.70B | $6.00M | $1.00M | $12.00M | $-40.00M | $-17.88B | $-94.00M | $-82.00M | $-1.34B | $-35.00M | $- | $1.00M | $-4.00M | $-156.00M |
Purchases of Investments | $-287.00M | $-20.00M | $-1.76B | $- | $- | $- | $-2.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Sales Maturities of Investments | $-111.00M | $47.00M | $64.00M | $- | $- | $- | $2.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Other Investing Activities | $204.00M | $52.00M | $71.00M | $18.00M | $60.00M | $-112.00M | $20.00M | $19.00M | $1.00M | $75.00M | $10.00M | $15.00M | $2.00M | $-4.00M | $-27.00M | $-5.00M | $1.00M | $9.00M | $-3.00M | $106.00M |
Net Cash Used for Investing Activities | $-3.58B | $-253.00M | $-2.03B | $-376.00M | $-1.18B | $-443.00M | $-3.14B | $-525.00M | $-545.00M | $-419.00M | $-670.00M | $-18.69B | $-616.00M | $-626.00M | $-2.00B | $-626.00M | $-365.00M | $-259.00M | $-260.00M | $-339.00M |
Debt Repayment | $-1.11B | $-1.00M | $1.21B | $-1.31B | $1.97B | $-1.32B | $504.00M | $3.49B | $-1.00M | $-1.82B | $-1.01B | $8.60B | $3.12B | $- | $-2.80B | $-1.00M | $-710.00M | $1.21B | $2.25B | $-4.65B |
Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $6.00M | $49.00M | $2.00M | $156.00M | $29.00M | $87.00M | $20.00M | $71.00M | $33.00M | $77.00M | $48.00M | $38.00M |
Common Stock Repurchased | $- | $- | $-3.00B | $- | $- | $- | $-3.00B | $-1.00B | $-6.00M | $- | $-2.00B | $-101.00M | $-2.00B | $-2.00B | $-2.00B | $-31.00M | $-1.50B | $-1.50B | $-1.50B | $-750.00M |
Dividends Paid | $-150.00M | $-149.00M | $-135.00M | $-136.00M | $-135.00M | $-135.00M | $-117.00M | $-117.00M | $-118.00M | $-117.00M | $-103.00M | $-103.00M | $-102.00M | $-103.00M | $-87.00M | $-87.00M | $-87.00M | $-87.00M | $-76.00M | $-76.00M |
Other Financing Activities | $67.00M | $36.00M | $109.00M | $14.00M | $18.00M | $4.00M | $20.00M | $20.00M | $-32.00M | $37.00M | $-34.00M | $-81.00M | $20.00M | $27.00M | $40.00M | $39.00M | $6.00M | $54.00M | $-50.00M | $4.96B |
Net Cash Used Provided by Financing Activities | $-1.19B | $-114.00M | $-1.82B | $-1.43B | $1.85B | $-1.46B | $-2.59B | $2.39B | $-151.00M | $-1.91B | $-3.15B | $8.47B | $3.04B | $-76.00M | $-4.85B | $-49.00M | $-791.00M | $1.18B | $619.00M | $-514.00M |
Effect of Forex Changes on Cash | $175.00M | $-15.00M | $22.00M | $10.00M | $-73.00M | $12.00M | $-31.00M | $250.00M | $-212.00M | $-78.00M | $-99.00M | $-20.00M | $-61.00M | $-93.00M | $137.00M | $102.00M | $181.00M | $20.00M | $-127.00M | $57.00M |
Net Change in Cash | $-2.41B | $1.58B | $-2.58B | $1.92B | $3.02B | $-347.00M | $-5.04B | $5.60B | $1.03B | $-874.00M | $-1.71B | $-7.56B | $5.01B | $1.43B | $-4.73B | $2.77B | $1.73B | $2.83B | $588.00M | $1.12B |
Cash at End of Period | $4.67B | $7.08B | $5.51B | $8.08B | $6.17B | $3.15B | $3.50B | $8.54B | $2.93B | $1.91B | $2.78B | $4.49B | $12.05B | $7.04B | $5.60B | $10.34B | $7.57B | $5.84B | $3.01B | $2.42B |
Cash at Beginning of Period | $7.08B | $5.51B | $8.08B | $6.16B | $3.15B | $3.50B | $8.54B | $2.93B | $1.91B | $2.78B | $4.49B | $12.05B | $7.04B | $5.60B | $10.34B | $7.57B | $5.84B | $3.01B | $2.42B | $1.30B |
Operating Cash Flow | $2.17B | $1.96B | $1.25B | $3.72B | $2.41B | $1.54B | $729.00M | $3.49B | $1.94B | $1.53B | $2.20B | $2.69B | $2.65B | $2.23B | $1.98B | $3.34B | $2.71B | $1.89B | $356.00M | $1.91B |
Capital Expenditure | $-272.00M | $-301.00M | $-347.00M | $-405.00M | $-332.00M | $-284.00M | $-458.00M | $-550.00M | $-547.00M | $-506.00M | $-640.00M | $-831.00M | $-524.00M | $-540.00M | $-628.00M | $-586.00M | $-366.00M | $-269.00M | $-253.00M | $-289.00M |
Free Cash Flow | $1.89B | $1.66B | $904.00M | $3.32B | $2.08B | $1.26B | $271.00M | $2.94B | $1.39B | $1.02B | $1.56B | $1.86B | $2.13B | $1.69B | $1.35B | $2.75B | $2.34B | $1.62B | $103.00M | $1.62B |
Thermo Fisher Scientific Stock Forecast
Analyst ratings, price targets, and earnings estimates for TMO.
TMO Analyst Ratings
Strong Buy
Based on 20 analysts in the past 3 months
TMO Stock 12 Month Forecast
$639.00
Based on 2 analysts in the last 3 months
Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Latest Price Target Updates
Date | Analyst | Firm | Price Target | Price When Posted | Upside |
---|---|---|---|---|---|
Jan 31, 2025 | Conor McNamara | RBC Capital | $693.00 | $597.75 | 15.9% |
Jan 02, 2025 | Vijay Kumar | Evercore ISI | $585.00 | $522.57 | 11.9% |
Oct 24, 2024 | Catherine Schulte | Robert W. Baird | $622.00 | $576.49 | 7.9% |
Oct 23, 2024 | Luke Sergott | Barclays | $610.00 | $570.92 | 6.8% |
Oct 01, 2024 | Vijay Kumar | Evercore ISI | $630.00 | $618.57 | 1.8% |
Sep 20, 2024 | Daniel Arias | Stifel Nicolaus | $680.00 | $620.25 | 9.6% |
Sep 20, 2024 | Catherine Schulte | Robert W. Baird | $632.00 | $620.25 | 1.9% |
Sep 19, 2024 | Patrick Donnelly | Citigroup | $620.00 | $617.11 | 0.5% |
Sep 18, 2024 | Justin Bowers | Deutsche Bank | $630.00 | $609.41 | 3.4% |
Sep 16, 2024 | Derik de Bruin | Bank of America Securities | $675.00 | $611.17 | 10.4% |
Thermo Fisher Scientific Dividends
Explore Thermo Fisher Scientific's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
0.29%
Dividend Payout Ratio
9.20%
Dividend Paid & Capex Coverage Ratio
4.37x
Thermo Fisher Scientific Dividend History
Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|
$0.39 | $0.39 | December 13, 2024 | December 13, 2024 | January 15, 2025 | November 07, 2024 |
$0.39 | $0.39 | September 13, 2024 | September 13, 2024 | January 15, 2025 | November 07, 2024 |
$0.39 | $0.39 | June 14, 2024 | June 14, 2024 | July 15, 2024 | May 22, 2024 |
$0.39 | $0.39 | March 14, 2024 | March 15, 2024 | April 15, 2024 | February 21, 2024 |
$0.35 | $0.35 | December 14, 2023 | December 15, 2023 | January 16, 2024 | November 09, 2023 |
$0.35 | $0.35 | September 14, 2023 | September 15, 2023 | October 13, 2023 | July 13, 2023 |
$0.35 | $0.35 | June 14, 2023 | June 15, 2023 | July 14, 2023 | May 24, 2023 |
$0.35 | $0.35 | March 14, 2023 | March 15, 2023 | April 14, 2023 | February 22, 2023 |
$0.3 | $0.3 | December 14, 2022 | December 15, 2022 | January 16, 2023 | November 10, 2022 |
$0.3 | $0.3 | September 14, 2022 | September 15, 2022 | October 14, 2022 | July 07, 2022 |
$0.3 | $0.3 | June 14, 2022 | June 15, 2022 | July 15, 2022 | May 18, 2022 |
$0.3 | $0.3 | March 15, 2022 | March 16, 2022 | April 14, 2022 | February 23, 2022 |
$0.26 | $0.26 | December 14, 2021 | December 15, 2021 | January 14, 2022 | November 04, 2021 |
$0.26 | $0.26 | September 14, 2021 | September 15, 2021 | October 15, 2021 | July 08, 2021 |
$0.26 | $0.26 | June 14, 2021 | June 15, 2021 | July 15, 2021 | May 19, 2021 |
$0.26 | $0.26 | March 15, 2021 | March 16, 2021 | April 16, 2021 | February 23, 2021 |
$0.22 | $0.22 | December 14, 2020 | December 15, 2020 | January 15, 2021 | November 05, 2020 |
$0.22 | $0.22 | September 14, 2020 | September 15, 2020 | October 15, 2020 | July 09, 2020 |
$0.22 | $0.22 | June 12, 2020 | June 15, 2020 | July 15, 2020 | May 20, 2020 |
$0.22 | $0.22 | March 13, 2020 | March 16, 2020 | April 16, 2020 | February 25, 2020 |
Peers: Medical - Diagnostics & Research
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
---|---|---|---|---|---|
![]() Agilent Technologies, Inc.
A
|
$42.33B | $148.39 | $4.43 | $29.42 | $6.43 |
![]() IDEXX Laboratories, Inc.
IDXX
|
$38.08B | $465.00 | $10.79 | $38.33 | $0.00 |
![]() Illumina, Inc.
ILMN
|
$18.00B | $113.52 | $-7.69 | $-17.37 | $0.00 |
![]() Waters Corporation
WAT
|
$24.59B | $414.19 | $10.87 | $30.28 | $16.91 |
![]() Danaher Corporation
DHR
|
$151.52B | $209.78 | $5.33 | $43.04 | $0.00 |
![]() Invitae Corporation
NVTA
|
$5.44M | $0.02 | $-13.18 | $-0.14 | $4.30 |
![]() Guardant Health, Inc.
GH
|
$5.53B | $44.76 | $-4.28 | $-6.32 | $19.09 |
![]() Mettler-Toledo International Inc.
MTD
|
$29.73B | $1408.80 | $40.67 | $30.09 | $0.00 |
![]() Charles River Laboratories International, Inc.
CRL
|
$8.50B | $166.15 | $9.27 | $25.52 | $3.37 |
![]() Revvity, Inc.
RVTY
|
$14.42B | $118.47 | $2.20 | $50.56 | $0.00 |
Related Metrics
Explore detailed financial metrics and analysis for TMO.